Yvonne Blaszczyk, president and CEO of BMG Group, sees the gold price hitting US$5,000 per ounce in Q1 on the back of a complex geopolitical landscape.
‘In terms of the geopolitical configuration of the world, we are witnessing history right now,’ she said.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
The S&P 500 ($SPX) just logged its fifth straight trading box breakout, which means that, of the five trading ranges the index has experienced since the April lows, all have been resolved to the upside.
How much longer can this last? That’s been the biggest question since the massive April 9 rally. Instead of assuming the market is due to roll over, it’s been more productive to track price action and watch for potential changes along the way. So far, drawdowns have been minimal, and breakouts keep occurring. Nothing in the price action hints at a lasting change — yet.
While some are calling this rally “historic,” we have a recent precedent. Recall that from late 2023 through early 2024, the index had a strong start and gave way to a consistent, steady trend.
From late October 2023 through March 2024, the S&P 500 logged seven consecutive trading box breakouts. That streak finally paused with a pullback from late March to early April, which, as we now know, was only a temporary hiccup. Once the bid returned, the S&P 500 went right back to carving new boxes and climbing higher.
If there’s been one gripe about this rally, it’s that the number of new highs within the index has lagged. As we’ve discussed before, among all the internal breadth indicators available, new highs almost always lag — that’s normal. What we really want to see is whether the number of new highs begins to exceed prior peaks as the market continues to rise, which it has, as shown by the blue line in the chart below.
As of Wednesday’s close, 100 S&P 500 stocks were either at new 52-week highs or within 3% of them. That’s a strong base. We expect this number to continue rising as the market climbs, especially if positive earnings reactions persist across sectors.
Even when we get that first day with 100+ S&P 500 stocks making new 52-week highs, though, it might not be the best time to initiate new longs.
The above chart shows that much needs to align for that many stocks to peak in unison, which has historically led to at least a short-term consolidation, if not deeper pullbacks — as highlighted in yellow. Every time is different, of course, but this is something to keep an eye on in the coming weeks.
The GoNoGo Trend remains in bullish mode, with the recent countertrend signals having yet to trigger a greater pullback.
We still have two live bullish upside targets of 6,555 and 6,745, which could be with us for a while going forward. For the S&P 500 to get there, it will need to form new, smaller versions of the trading boxes.
In the chart below, you can view a rising wedge pattern on the recent price action, the third since April. The prior two wedges broke down briefly and did not lead to a major downturn. The largest pullbacks in each case occurred after the S&P 500 dipped below the lower trendline of the pattern.
The deepest drawdown so far is 3.5%, which is not exactly a game-changer. Without downside follow-through, a classic bearish pattern simply can’t be formed, let alone be broken down from.
We’ll continue to monitor these formations as they develop because, at some point, that will change.
The copper price climbed to a fresh record on Tuesday (January 6), with persistent supply disruptions and trade uncertainty pushing the metal to a nearly 30 percent rally since October.
Benchmark three month copper on the London Metal Exchange (LME) rose as much as 3.1 percent in early trading to an all‑time high of US$13,387.50 per metric ton before settling slightly lower, but still above US$13,200.
The jump marks another milestone in a rally that first saw copper breach US$12,000 late in December last year.
Copper is widely used across the industrial economy, from construction and power infrastructure to electric vehicles and data centers that support artificial intelligence growth. Analysts attribute the gains to a combination of production setbacks at major mines and heightened concerns that prospective US trade tariffs could further disrupt flows.
Large copper-mining operations such as Freeport-McMoRan’s (NYSE:FCX) Grasberg complex in Indonesia have faced challenges since last year, while a strike at Capstone Copper’s (TSX:CS,ASX:CSC,OTC Pink:CSCCF) Mantoverde mine in Chile has reduced output prospects in one of the world’s top copper‑producing nations.
The threat of new tariffs under the Trump administration has also shaped expectations. Traders have moved to ship refined copper into the US ahead of any potential levies, tightening supply elsewhere. Furthermore, data show copper stocks in Comex warehouses have jumped to more than 450,000 metric tons, well above last year’s levels.
Market watchers expect many of the forces that drove copper through 2025 to persist.
Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.
Copper demand is projected to grow as the global energy transition accelerates.
“A huge amount of this tightness has to do with US tariff concerns,” she said.
China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.
Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.
A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.
Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.
Alain Corbani, head of mining at Montbleu Finance and manager of the Global Gold and Precious Fund, sees the gold price reaching US$5,000 per ounce in the near term.
He sees real interest rates and the US dollar as the key factors to watch, but noted that other elements are also adding tailwinds.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
The S&P 500 ($SPX) just logged its fifth straight trading box breakout, which means that, of the five trading ranges the index has experienced since the April lows, all have been resolved to the upside.
How much longer can this last? That’s been the biggest question since the massive April 9 rally. Instead of assuming the market is due to roll over, it’s been more productive to track price action and watch for potential changes along the way. So far, drawdowns have been minimal, and breakouts keep occurring. Nothing in the price action hints at a lasting change — yet.
While some are calling this rally “historic,” we have a recent precedent. Recall that from late 2023 through early 2024, the index had a strong start and gave way to a consistent, steady trend.
From late October 2023 through March 2024, the S&P 500 logged seven consecutive trading box breakouts. That streak finally paused with a pullback from late March to early April, which, as we now know, was only a temporary hiccup. Once the bid returned, the S&P 500 went right back to carving new boxes and climbing higher.
If there’s been one gripe about this rally, it’s that the number of new highs within the index has lagged. As we’ve discussed before, among all the internal breadth indicators available, new highs almost always lag — that’s normal. What we really want to see is whether the number of new highs begins to exceed prior peaks as the market continues to rise, which it has, as shown by the blue line in the chart below.
As of Wednesday’s close, 100 S&P 500 stocks were either at new 52-week highs or within 3% of them. That’s a strong base. We expect this number to continue rising as the market climbs, especially if positive earnings reactions persist across sectors.
Even when we get that first day with 100+ S&P 500 stocks making new 52-week highs, though, it might not be the best time to initiate new longs.
The above chart shows that much needs to align for that many stocks to peak in unison, which has historically led to at least a short-term consolidation, if not deeper pullbacks — as highlighted in yellow. Every time is different, of course, but this is something to keep an eye on in the coming weeks.
The GoNoGo Trend remains in bullish mode, with the recent countertrend signals having yet to trigger a greater pullback.
We still have two live bullish upside targets of 6,555 and 6,745, which could be with us for a while going forward. For the S&P 500 to get there, it will need to form new, smaller versions of the trading boxes.
In the chart below, you can view a rising wedge pattern on the recent price action, the third since April. The prior two wedges broke down briefly and did not lead to a major downturn. The largest pullbacks in each case occurred after the S&P 500 dipped below the lower trendline of the pattern.
The deepest drawdown so far is 3.5%, which is not exactly a game-changer. Without downside follow-through, a classic bearish pattern simply can’t be formed, let alone be broken down from.
We’ll continue to monitor these formations as they develop because, at some point, that will change.
2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024.
Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired distressed assets, alongside pivotal regulatory developments.
The central theme for the year was the expected US federal shift to Schedule III, a policy rollercoaster that culminated in an executive order to expedite rescheduling, focusing investor flows into scaled, cashflow-positive MSOs.
Internationally, incremental legalization in Europe, particularly the momentum in Germany, broadened the global footprint and provided new export channels for North American producers.
Within market trends, profitability pivoted away from bulk flower to high-margin consumables, with infused pre-rolls and edibles driving category growth and supporting a rerating of resilient operators.
After 2024’s punishing drawdowns, cannabis navigated a high-stakes policy rollercoaster in 2025.
The sector bottomed in Q1 as anticipated US Drug Enforcement Administration (DEA) rescheduling hearings were delayed, but ignited in late Q3 and Q4 as the narrative shifted toward a decisive executive-led reclassification.
This momentum culminated in US President Donald Trump’s December 18 executive order, which expedites rescheduling and CBD access. It triggered a parabolic surge followed by a violent ‘sell the news’ correction.
“Cannabis is not just a volatile sector or industry. It is the most volatile place,” said Dan Ahrens, managing director and portfolio manager of the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS). “It just proves the point, once again, that we really, really need this federal reform to be officially completed.”
Indeed, 2025 brought plenty of ups and downs. The year opened with Schedule III buzz, which came after prior Department of Health and Human Services recommendations and initial DEA scheduling proposals from late 2024; however, proceedings ground to a halt after the DEA postponed a key January hearing by over 180 days due to administrative turnover, bias claims and leadership gaps post-election. These disruptiosn kept Section 280E tax penalties in place and banking access frozen, keeping margins for MSOs compressed.
Meanwhile, House spending bills included language prohibiting the Department of Justice (DoJ) from spending any funds on rescheduling efforts, while Senate Farm Bill revisions redefined hemp to exclude intoxicating derivatives like delta-8 THC, capping them at trace levels and effectively imposing a nationwide hemp ban on high-potency alternatives.
The MSOS ETF’s portfolio construction exemplified the broader trend of investor flows concentrating into scaled, cash-flow-positive MSOs amid reform volatility. The fund’s top three holdings — Curaleaf Holdings (CSE:CURA,OTCQX:CURLF), Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) and Green Thumb Industries (CSE:GTII,OTCQX:GTBIF) — accounted for over 68 percent of its total holdings as of December 31, underscoring confidence in these operators as resilient proxies for US cannabis maturation while smaller single-state players face dilution.
MSOS managers reinforced the shift in the year’s third quarter by trimming three underperformers from the ETF: 4Front Ventures (CSE:FFNT), Lowell Farms (CSE:LOWL) and Gold Flora.
Despite stalls in momentum, Trump kept hope alive in the cannabis sector throughout the year.
In September, he called cannabis reform an “80-20 issue” with broad public backing, and posted a Truth Social video promoting CBD for seniors and suggesting Medicaid coverage.
Those moves, alongside Representative Greg Steube’s (R-FL) Marijuana 1-to-3 Act, aimed at legislatively shifting cannabis to Schedule III, drove a surge in Q3 without any underlying procedural progress.
As mentioned, the December 18 executive order injected fresh life into the sector, directing the DoJ and DEA to expedite cannabis rescheduling to Schedule III, while launching a CMS Innovation Center pilot for federal health programs to cover hemp-derived CBD as early as April 2026, with up to US$500 annual reimbursement for eligible patients.
CMS Administrator Mehmet Oz previously endorsed Medicare reimbursement for CBD therapies during his confirmation hearings, framing them as “low-risk, high-impact” options for age-related ailments.
2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.
This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.
The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.
In 2025, cannabis companies pivoted toward operational resilience and product innovation amid persistent commoditization pressures. After 2024’s wholesale flower price declines, down roughly 32 percent since 2021 by some estimates, stronger MSOs like Tilray Brands (TSX:TLRY,NASDAQ:TLRY) are demonstrating pricing power through branded products and category expansion into edibles, vapes and infused pre-rolls.
Deal flow rebounded from 2024’s US$1.17 billion trough, with US transactions reaching US$2.1 billion.
Against that backdrop, cash-rich MSOs pursued distressed roll-ups in oversupplied states like California and New York, with Vireo Growth’s (CSE:VREO,OTCQX:VREOF) acquisitions in Minnesota and New York exemplifying the trend, achieving critical mass with premium valuations amid hemp restrictions.
Private equity and creative deal structures dominated in the cannabis market, preparing operators for federal reform, while consolidating fragmented retail.
2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.
“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.
Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.
While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.
Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).
Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.
Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.
All data was compiled on December 31, 2025, using TradingView’s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.
Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50
MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.
The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.
In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.
Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82
KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.
Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.
KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.
The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.
Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19
Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.
Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.
In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.
The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
The S&P 500 ($SPX) just logged its fifth straight trading box breakout, which means that, of the five trading ranges the index has experienced since the April lows, all have been resolved to the upside.
How much longer can this last? That’s been the biggest question since the massive April 9 rally. Instead of assuming the market is due to roll over, it’s been more productive to track price action and watch for potential changes along the way. So far, drawdowns have been minimal, and breakouts keep occurring. Nothing in the price action hints at a lasting change — yet.
While some are calling this rally “historic,” we have a recent precedent. Recall that from late 2023 through early 2024, the index had a strong start and gave way to a consistent, steady trend.
From late October 2023 through March 2024, the S&P 500 logged seven consecutive trading box breakouts. That streak finally paused with a pullback from late March to early April, which, as we now know, was only a temporary hiccup. Once the bid returned, the S&P 500 went right back to carving new boxes and climbing higher.
If there’s been one gripe about this rally, it’s that the number of new highs within the index has lagged. As we’ve discussed before, among all the internal breadth indicators available, new highs almost always lag — that’s normal. What we really want to see is whether the number of new highs begins to exceed prior peaks as the market continues to rise, which it has, as shown by the blue line in the chart below.
As of Wednesday’s close, 100 S&P 500 stocks were either at new 52-week highs or within 3% of them. That’s a strong base. We expect this number to continue rising as the market climbs, especially if positive earnings reactions persist across sectors.
Even when we get that first day with 100+ S&P 500 stocks making new 52-week highs, though, it might not be the best time to initiate new longs.
The above chart shows that much needs to align for that many stocks to peak in unison, which has historically led to at least a short-term consolidation, if not deeper pullbacks — as highlighted in yellow. Every time is different, of course, but this is something to keep an eye on in the coming weeks.
The GoNoGo Trend remains in bullish mode, with the recent countertrend signals having yet to trigger a greater pullback.
We still have two live bullish upside targets of 6,555 and 6,745, which could be with us for a while going forward. For the S&P 500 to get there, it will need to form new, smaller versions of the trading boxes.
In the chart below, you can view a rising wedge pattern on the recent price action, the third since April. The prior two wedges broke down briefly and did not lead to a major downturn. The largest pullbacks in each case occurred after the S&P 500 dipped below the lower trendline of the pattern.
The deepest drawdown so far is 3.5%, which is not exactly a game-changer. Without downside follow-through, a classic bearish pattern simply can’t be formed, let alone be broken down from.
We’ll continue to monitor these formations as they develop because, at some point, that will change.
From established players to up-and-coming firms, Canada’s pharmaceutical landscape is diverse and dynamic.
Canadian drug companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.
Read on to learn about what’s been driving the share prices of the best-performing Canadian pharma stocks.
Year-on-year gain: 26.6 percent
Market cap: C$149.8 million
Share price: C$4.76
HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. The company specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia.
HLS in-licensed the exclusive rights to the treatments Nilemdo and Nexlizet, both of which are already approved in other countries, from Esperion (NASDAQ:ESPR) in May.
The November 2025 Health Canada approval of LDL-cholesterol lowering treatment Nilemdo represents the most significant catalyst for the company since the launch of Vascepa, positioning HLS as a dominant leader in the Canadian cardiovascular market. The company is targeting Nilemdo’s commercial launch in Q2 2026.
Along with the approval, Health Canada issued a notice of non-compliance for its Nexlizet cholesterol-reducing treatment. According to HLS, the decision was related to chemistry, manufacture and controls data, not clinical data or safety.
Additionally, the company generates revenue from a diversified portfolio of royalty interests on various products marketed by third parties.
Year-on-year gain: 14.49 percent
Market cap: C$141.04 million
Share price: C$0.79
Satellos Bioscience is a Canadian pharmaceutical company expanding treatment options for muscle disorders. The company has focused specifically on Duchenne muscular dystrophy, developing therapies that target the specific biological pathways involved in regenerating and repairing muscle tissue.
Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.
In Q4 2025, Satellos administered the first dose to a patient in its 11-month open-label follow-up study for adults who completed its initial Phase 1b trial. The study seeks to demonstrate the lasting impact of the significant functional improvements observed earlier in the year.
On December 9, the company received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.
Year-on-year gain: 14.29 percent
Market cap: C$592.59 million
Share price: C$6.00
Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Québec. It operates on an acquisition and in-licensing model, obtaining the rights to innovative medicines from global pharmaceutical companies and commercializing them across Canada and Latin America.
The company was originally founded by the former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought the Paladin business back from Endo for C$107 million, adding over 40 products to Knight’s Canadian roster.
The additions, helped drive 32 percent revenue growth year-over-year to a record C$122.55 million in Q3. The company projects its Knight Canada subsidiary will be the company’s top revenue-contributor within two years.
Year-on-year gain: 10.07 percent
Market cap: C$146.89 million
Share price: C$12.90
BioSyent is a specialty pharmaceutical company focused on in-licensing or acquiring established, high-margin healthcare products for the Canadian and international markets. Its growth is anchored by brands in iron health and women’s wellness. Its flagship brand, FeraMAX, has been Canada’s leading iron supplement for over a decade.
The company’s 2024 acquisition of Tibella, a treatment for menopausal symptoms, has been a major growth driver. According to its Q3 earnings report. BioSyent’s sales grew 19 percent year-over-year in Canada and 94 percent in the international market.
Year-on-year gain: 6.45 percent
Market cap: C$47.54 million
Share price: C$0.66
NurExone Biologic is behind ExoTherapy, a drug-delivery platform that uses exosomes, which are nano-sized extracellular vesicles, to create treatments for central nervous system disorders, spinal cord injuries and traumatic brain injuries. It is a less invasive alternative to cell transplantation, which requires surgery and carries the risk of rejection.
NurExone’s first nano-drug, ExoPTEN, uses a proprietary sIRNA sequence delivered with the ExoTherapy platform to treat spinal cord injuries. ExoPTEN received orphan drug designation from the US FDA in October 2023.
The company expects to initiate its Phase 1/2a first-in-human trial for acute spinal cord injury in the second half of 2026, targeting patients with traumatic injuries.
It continues to make significant progress, with recent preclinical studies demonstrating strong, dose-dependent vision recovery in glaucoma models and improved motor function in spinal cord injury models.
The company announced plans for a US exosome production facility in Indianapolis, Indiana, in September. According to the release, ‘The GMP compliant site would produce exosomes both for NurExone’s therapeutic pipeline and for a growing business-to-business opportunity in regenerative aesthetics.’
In December, the company began planning for small-scale production of ExoPTEN in Israel to support its clinical trial.
Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.
Centurion Minerals offers investors an early-stage entry point into a strategically located gold exploration company positioned within one of North America’s most prolific and active mining districts. With a restructured corporate foundation, and a highly experienced geological and corporate finance team, the company is primed for value-creating discoveries.
Centurion Minerals (TSXV:CTN) is a Canadian exploration company focused on the acquisition, exploration and development of precious metals projects in the Americas.
The company’s strategy is centered on advancing high-quality, early-stage gold assets through systematic exploration to define drill-ready targets and unlock the discovery potential inherent in its three-part claim package: the Newman, Noseworthy and Hepburn properties. Situated near major operations and new discoveries, these claims benefit from excellent infrastructure, year-round road access and proximity to proven mineralized structural corridors. Centurion intends to increase shareholder value through targeted geophysics, ground truthing and drilling programs designed to reveal new high-grade zones, as well as through potential future acquisitions of complementary gold assets across the Americas.
Backed by a leadership team with decades of exploration, geology, corporate finance and project development experience, Centurion is positioned to capitalize on strong gold market fundamentals and renewed investor interest in junior exploration companies. With a low current valuation and advancing work program, the company provides leverage to both exploration success and broader trends in the gold sector.
The Casa Berardi West project is Centurion’s flagship gold exploration asset, encompassing approximately 6,732 hectares across three contiguous claim groups – Newman, Noseworthy and Hepburn – located 66 km northeast of Cochrane, Ontario. The project sits along structural corridors that host some of the region’s most significant deposits, including Hecla Mining’s Casa Berardi mine (3 Moz past production, plus 4 Moz in reserves and resources), Agnico Eagle’s Detour Lake mine (15 Moz reserve, producing ~659,000 oz of gold per year ), and AMEX Exploration’s Perron discovery (1.6 Moz measured and indicated resource at 6.14 g/t gold).
Location of the three claim groups at Casa Berardi West
The project is situated within the central north Abitibi Subprovince, an Archean greenstone belt known globally for its prolific endowment of gold and base metals. The claims lie adjacent to geological features associated with multiple major deposits – iron formations, shear zones and VMS trends – creating strong analogues to high-grade gold mines such as the Musselwhite mine in Northern Ontario.
This “closeology” positioning significantly enhances the potential for Centurion’s ground to host similar mineralization.
Historic exploration across the Casa Berardi West project – spanning more than 70 RC and diamond drill holes – has already confirmed the presence of gold-bearing structures and favorable host rocks. Notably, previous work returned multiple samples above 1 g/t gold, including a standout result of 38 g/t gold, demonstrating strong mineralization potential across the claim area.
Significant historic drill results at Newman target
Across the three claim groups, drilling and geophysical surveys have identified key geological features associated with major deposits in the region, including iron formations, shear zones and sulphidized horizons. Several zones of interest remain untested or underexplored, particularly along structural trends that extend from nearby high-grade gold and VMS systems such as the Perron and Normetal areas.
These findings provide Centurion with multiple high-priority target areas for follow-up exploration, forming the foundation for its next phase of geophysical work and upcoming drill targeting.
David Tafel brings over 30 years of experience in corporate structuring, strategic planning, financing and executive management across multiple public and private resource companies. He has raised several hundred million dollars for ventures in mining, technology and life sciences, and previously managed private investment funds at Canada’s largest independent securities firm.
A seasoned financial executive with more than 20 years of experience, Jeremy Wright serves as president & CEO of Seatrend Strategy Group and has held CFO roles across numerous public companies in the resource and technology sectors. His background includes financial management, negotiations and environmental economics, supported by extensive board leadership experience.
Joseph Del Campo has served as CFO and Interim CEO across several mining companies, including Unigold and First Nickel. With decades of corporate financial leadership and board experience, he contributes deep governance, audit and operational oversight expertise to Centurion’s board.
A veteran geologist with 40+ years of industry experience, Mike Kilbourne has managed over 100,000 metres of drilling across North America and Mexico, worked as a production geologist in multiple mining environments, and generated over 700 exploration targets for private and public companies.
Jamie Lavigne is a senior exploration geologist with more than 30 years of experience in base and precious metals. He has held senior technical roles with major mining companies and specializes in advanced exploration, resource delineation and geological modeling across global mineral belts.